Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
37.42
-0.53 (-1.40%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.41 - 38.07
52 week 35.15 - 46.80
Open 37.92
Vol / Avg. 0.00/3.29M
Mkt cap 10.50B
P/E 13.97
Div/yield     -
EPS 2.68
Shares 280.47M
Beta 0.90
Inst. own 102%
Oct 31, 2017
Q4 2017 Hologic Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 11, 2017
Hologic Inc at Morgan Stanley Healthcare Conference - 9:55AM EDT - Add to calendar
Aug 9, 2017
Hologic Inc at Canaccord Genuity Growth Conference - Webcast
Aug 2, 2017
Q3 2017 Hologic Inc Earnings Call - Webcast
Aug 2, 2017
Q3 2017 Hologic Inc Earnings Release
Jun 15, 2017
Hologic Inc at William Blair Growth Stock Conference - Webcast
Jun 13, 2017
Hologic Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 6, 2017
Hologic Inc at Jefferies Healthcare Conference - Webcast
May 23, 2017
Hologic Inc at UBS Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '17) 2016
Net profit margin 7.38% 11.68%
Operating margin 13.94% 19.18%
EBITD margin - 36.16%
Return on average assets 2.84% 4.42%
Return on average equity 8.43% 15.67%
Employees 5,333 -
CDP Score - -

Address

250 Campus Dr
MARLBOROUGH, MA 01752-3020
United States - Map
+1-508-2632900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Officers and directors

Stephen P. MacMillan Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Robert W. McMahon Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Sanjay Prabhakaran Regional President - Asia
Bio & Compensation  - Reuters
Peter J. Valenti III Division President- Breast and Skeletal Health
Age: 53
Bio & Compensation  - Reuters
Jan Verstreken Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
Bio & Compensation  - Reuters
Thomas A. West Division President- Diagnostics
Age: 53
Bio & Compensation  - Reuters
Eric B. Compton Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Michael J. Watts Vice President, IR Contact Officer
Bio & Compensation  - Reuters
John M. Griffin General Counsel
Age: 56
Bio & Compensation  - Reuters
Elaine S. Ullian Lead Independent Director
Age: 69
Bio & Compensation  - Reuters